Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US
February 15, 2023
Ryan Allway February 15th, 2023 Psychedelics, Top News The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc’s Cannamide™ and classical psychedelics Tel Aviv, Israel / Vancouver, Canada, Feb. 15, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND),... Read more
Ryan Allway January 11th, 2022 Psychedelics TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ — SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the “Company”), announced that it has begun to examine the possibility of including psychedelic... Read more
Clearmind Announces Changes To Senior Management As It Accelerates Development Of Its IP Portfolio
July 14, 2021
Ryan Allway July 14th, 2021 Psychedelics Industry Veteran Dr. Adi Zuloff-Shani Takes The Helm As CEO Toronto, Ontario–(Newsfile Corp. – July 14, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve... Read more
